The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases—A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial.
C. C. Schimanski
Employment or Leadership Position - Merck KGaA (I)
Consultant or Advisory Role - Merck KGaA
Honoraria - Merck KGaA
P. R. Galle
No relevant relationships to disclose
H. Lang
No relevant relationships to disclose
M. Schoen
No relevant relationships to disclose
M. H. Moehler
Honoraria - Merck KGaA
Research Funding - Merck KGaA